The new Global Challenge campaign aims to mobilise collaboration between academia and industry to address unmet medical needs in rare diseases. IN-PART is inviting the tech transfer community and academic researchers to share non-confidential details of rare diseases research and technologies.
There are no associated costs or requirements for an IN-PART subscription to engage with this campaign. The Global Challenge campaign will be open to academia from Tuesday the 30th of May to Tuesday the 11th of July.
Tech transfer offices and academics can submit technologies in their portfolio related to the campaign through this submission form. Then, the submissions will proactively be disseminated to IN-PART’s global network of industry R&D teams with aligned interests, including their headline campaign partners: Mitsubishi Tanabe Pharma, General Inception, Ultragenyx, Sanofi, and Global Genes/RARE-X. Each partner has shared their R&D priorities and technical needs as part of this campaign. Further details about the scope of opportunities sought can be found on the campaign landing page and submission form.
Alongside the Global Challenge campaign, IN-PART is running a Virtual Series, which includes industry partnering opportunities with their industry campaign partners and a non-profit partnering event with Global Genes, as well as an academic showcase event. The event programme is also free to attend, and a recording will be circulated afterwards to those who sign up.
